Back to School: How biopharma can reboot drug development. Access exclusive analysis here

A-002: Completed Phase II enrollment

Anthera completed enrollment of about 400 patients in the double-blind, international

Read the full 119 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE